296 related articles for article (PubMed ID: 9675551)
1. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
[TBL] [Abstract][Full Text] [Related]
2. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of imipenem against gram-positive and gram-negative aerobic bacteria from clinical isolates.
Bastianini L; Sposini T; Bartoli A; Marconi P
Microbiologica; 1988 Apr; 11(2):137-42. PubMed ID: 3165489
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
[TBL] [Abstract][Full Text] [Related]
8. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Chen MJ; Wang H;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
Platsouka E; Zissis NP; Constantoulaki S; Paniara O
J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
[TBL] [Abstract][Full Text] [Related]
11. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
12. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
13. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the antibiotic susceptibility patterns of pathogens causing nosocomial infections.
Yaman A; Tasova Y; Kibar F; Inal AS; Saltoglu N; Buyukcelik O; Kurtaran B; Dundar IH
Saudi Med J; 2004 Oct; 25(10):1403-9. PubMed ID: 15494811
[TBL] [Abstract][Full Text] [Related]
15. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
[TBL] [Abstract][Full Text] [Related]
17. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
